Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: Clinical and immunological evaluation of a phase I trial

Cancer Immunology, Immunotherapy

Volumn 51, Issue 1, 2002, Pages 45-52

  Hernando, Juan ^a   Park, Tjoung Won ^a   Kübler, Kirsten ^a   Offergeld, Ruth ^a   Schlebusch, Harald ^b   Bauknecht, Thomas ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Dendritic cell; Immunotherapy; Ovarian carcinoma

Indexed keywords

CA 125 ANTIGEN; GAMMA INTERFERON; KEYHOLE LIMPET HEMOCYANIN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DISEASE COURSE; DRUG SAFETY; DRUG TOLERANCE; ERYTHEMA; EVALUATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOCOMPETENCE; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TH1 CELL; TUMOR GROWTH; UTERUS SARCOMA; VACCINATION;

ADULT; ANTIGEN PRESENTATION; CANCER VACCINES; CARCINOMA; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DRUG ERUPTIONS; FEMALE; HEMOCYANIN; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOCOMPETENCE; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MIDDLE AGED; OVARIAN NEOPLASMS; SARCOMA; TH1 CELLS; TREATMENT OUTCOME; UTERINE NEOPLASMS; VACCINATION;

EID: 0036181959     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-001-0255-1     Document Type: Article

References (37)

1. Immunobiology of dendritic cells
2. Induction of cytotoxic T lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
3. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
4. Immunization with tumor cell lysate-loaded autologous antigen-presenting cell-based vaccine in melanoma
5. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
6. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
7. Dendritic cells in cancer immunotherapy
8. Vaccine therapy of pediatric solid tumors with tumor lysate-pulsed dendritic cells
9. Dendritic cells: Unique leukocyte populations which control the primary immune response
10. Cellular and humoral responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
11. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
12. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
13. Isolation and characterization of ovarian cancer antigen CA-125 using a new monoclonal antibody (VK-8): Identification as a mucin-type molecule
14. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial
15. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
16. Strategies for immunotherapy of cancer
17. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
18. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
19. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: The result of a retrospective study of 423 cases of uterine sarcoma
20. Cancer vaccines
21. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
22. Cytokines and chemokines in T lymphopoiesis and T cell effector function
23. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability
24. + cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer
25. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein
26. Modulation of TCR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients
27. MUC1 and cancer
28. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
29. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
30. Dendritic cell vaccines for cancer immunotherapy
31. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells
32. Antigen-pulsed dendritic cell therapy for hormone-refractory prostate cancer: A phase I/II trial
33. T cell defined antigens
34. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: Identification of human leukocyte antigen class II restricted epitopes
35. Ovarian cancer: Age, contrasts in incidence, histology, disease stage at diagnosis and mortality
36. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily
37. Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells